• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Analyse

Rovsing (One-pager): Rights issue and record tender activity set the stage for the next cycle

Af Michael FriisHead of Equities
Rovsing
Download analyse (PDF)

Oversigt

  • Rovsing's Q3 report showed sequential improvement with revenue of DKK 9.2 million and EBITDA near breakeven, but the company expects to meet the low end of its full-year guidance.
  • The rights issue, fully guaranteed with gross proceeds of DKK 10.4 million, aims to reduce debt and fund growth initiatives under the Buy & Build strategy.
  • The investment case is driven by a DKK 140 million tender pipeline and the Buy & Build strategy, with potential for significant order intake as the new ESA budget cycle begins.
  • Rovsing trades at a discount with an EV/Sales of 1.2x for 2025/26E, which could narrow if order intake aligns with the tender pipeline.

This content is generated by AI. You can give feedback on it in the Inderes forum.

In connection with Rovsing's Q3 report and rights issue announcement for the financial year 2025/26, we have updated our investment case one-pager.

Q3 showed a sequential improvement following a challenging first half, with revenue of DKK 9.2 million versus DKK 7.5 million in Q3 2024/25 and EBITDA near breakeven versus DKK -0.4 million a year earlier. Nonetheless, the company expects to land at the low end of its revised full-year guidance, implying revenue of approximately DKK 33 million and EBITDA at the lower bound of the DKK -2.5 to 0.5 million range. The order backlog has declined to DKK 25.9 million from DKK 33.1 million at the end of H1 — reflecting deliveries progressing — but the more significant forward-looking signal is the DKK 140 million in submitted binding proposals on upcoming European flagship missions, which highlights the step-change in tender activity as the new ESA budget cycle gets underway.

The rights issue, with gross proceeds of DKK 10.4 million at a subscription price of DKK 30 per share, is fully guaranteed and carries no financing risk. Proceeds are earmarked for debt reduction and to fund growth initiatives under the Buy & Build strategy.

The investment case rests on two interconnected catalysts. First, the conversion of the DKK 140 million tender pipeline into order intake as ESA and European national programmes begin awarding contracts under the new budget cycle, a cycle approximately 30% larger than the previous one. With a build-to-book ratio of around 1, an orderbook that approaches the prior cycle peak of DKK 65 million would meaningfully change the financial profile. Second, the Buy & Build strategy offers a path to accelerated growth and improved investor visibility, as demonstrated by peers such as Scandinavian Astor Group. The rights issue provides the capital foundation to pursue both.

The key risks remain consistent with our prior analysis: project delays outside the company's control, execution risk on the Buy & Build strategy, uncertainty around U.S. space policy under the new administration, and near-term share price volatility related to the rights issue process. The CEO transition adds a layer of uncertainty, though the fully guaranteed financing removes one overhang.

On valuation, Rovsing trades at EV/Sales of 1.2x for 2025/26E versus a peer median above 3x — a discount that reflects the current earnings pressure, but which could narrow materially if order intake accelerates in line with the tender pipeline.

For more details on the current results and the rationale behind the rights issue watch our event with the management.

Rovsing - Q3 2025/26 Event

Disclaimer: HC Andersen Capital receives payment from Rovsing for a Digital IR subscription agreement. HC Andersen Capital is furthermore acting as financial and legal advisor to the company in connection with an ongoing capital raise and receives payment from the company in this regard. Michael Friis, 07:30, 08/05/2026.

Rovsing er en teknologi virksomhed. Virksomheden har specialiseret sig som teknisk udvikler af testsystemer, produkter og tjenester til satellitter. Virksomheden udvikler system, produkter og softwareløsninger til satellit- og rumindustrien. Eksempler på løsninger, som virksomheden udvikler, omfatter check-out og valideringssystemer samt tilhørende ingeniørtjenester. Virksomheden blev grundlagt i 1992 og har sit hovedkontor med beliggenhed i Glostrup.

Læs mere på virksomhedsside